Synonyms: Anhydrous Tacrolimus; Anhydrous, Tacrolimus; Tacrolimus; DB00864; NSC-758659; IDI1_001040; NCGC00163470-01; NCGC00163470-02; NCGC00163470-04; NCGC00163470-05; NCGC00163470-06; NCGC00163470-07; BC205151; Tacrolimus Anhydrous; HY-13756; SC-13591; Fujimycin|||FK-506|||FR-900506; SBI-0052894.P002; AB0012538; CAS-104987-11-3; FT-0082660; M2258; C01375; D08556; Tacrolimus, Anhydrous; EN300-221601; W-1246; AB01209746-01; AB01209746_03; 581T933; Q-201775; SR-05000001879-1; SR-05000001879-2; SR-05000001879-5; BRD-K35452788-001-02-1; tacrolimus; BRD-K69608737-001-03-7; BRD-K69608737-001-10-2; [(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethenyl]-14,16-; 15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,; (3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone; (3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethenyl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-prop-2-en-1-yl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone; (E)-(1R,9S,12S,13R,14R,21S,23S,24R,25S,27R)-17-Allyl-1,14-dihydroxy-12-[(E)-2-((3R,4R)-4-hydroxy-3-methoxy-cyclohexyl)-1-methyl-vinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo[22.3.1.0*4,9*]octacos-18-ene-2,3,10,16-tetraone; 15,19-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone, 5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-[(1E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyc; 4,5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-heptadecahydro-5,19-dihydroxy-3-; dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-,(3S,4R,5S,8R,12S,14S,15R,16S,18R,19R,26aS)-; 104987-11-3; lohexyl]-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propen-1-yl)-, (3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-; Tacrolimus solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material; TacroBell; Tacrolimus hydrate; Advagraf (TN); Protopic (TN); Anhydrous, Tacrolimus; Tacrolimus (Prograf); D06OMK; TACROLIMUS MONOHYDRATE; Prograf; Tacrolimus [USAN:BAN:INN]; CID445643; C44-H69-N-O12; ACN-036876; CB10275; Tacrolimus, 98.5% - 10MG 10mg; B2143; D016559; 15,19-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone; 15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone; Protopic; 15 19-Epoxy-3H-pyrido[2 1-c][1 4]oxaazacyclotricosine-1 7 20 21(4H 23H)-tetrone 5 6 8 11 12 13 14 15 16 17 18 19 24 25 26 26a-hexadecahydro-5 19-dihydroxy-3-[(1E)-2-[(1R 3R 4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethenyl]-14 16-dimethoxy-4 10 12 18-tet; 15 19-Epoxy-3H-pyrido[2 1-c][1 4]oxaazacyclotricosine-1 7 20 21(4H 23H)-tetrone 5 6 8 11 12 13 14 15 16 17 18 19 24 25 26 26a-hexadecahydro-5 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14 16-dimethoxy-4 10 12 18-tetramethyl-8-(2-pr; 15,19-epoxi-3h-pirido[2,1-c][1,4]oxaazaciclotricosina-1,7,20,21(4h,23h)-tetrona, 5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahidro-5,19-dihidroxi-3-[(1e)-2-[(1r,3r,4r)-4-hidroxi-3-metoxiciclohexil]-1-metiletenil]-14,16-dimetoxi-4,10,12,18-tetram; 15,19-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone, 5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-(2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl)-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-, monohydrate, (3S-(3R*(E(1S*,3S*,4S*)),4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*))-; TAC; Fujimycin; Tsukubaenolide; FK506; FK 506; Tacrolimus anhydrous; Modigraf; Protopy; LCP-Tacro; Fk-506; FK 506; Anhydrous Tacrolimus; tacrolimus (fk506); FR-900506; Advagraf; FK-506; 8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN; UNII-Y5L2157C4J; K506; Astagraf XL; (-)-FK 506; Prograf (TN); FR900506; Tacarolimus; CHEMBL269732; CHEBI:61049; FK506; FR 900506; Y5L2157C4J; MFCD11045918; FK5; 109581-93-3; Tacrolimus (anhydrous); NCGC00163470-03; Prograft; Tacrolimus [USAN]; CCRIS 7124; FR 900506; Avagraf; Envarsus; Graceptor; L 679934; Envarsus XR; (3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-Hexadecahydro-5,19-dihydroxy-3-[(1E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propen-1-yl)-15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)tetrone; Tacrolimus (INN); FK-506 (Tacrolimus); Tacrolimus, anhydrous; SR-05000001879; FR-900506; Tacrolimus [USAN:INN]; Hecoria; Talymus; HSDB 8195; FK-506/Tacrolimus; PubChem18875; AC1L9IBU; SCHEMBL3088; DSSTox_CID_26354; DSSTox_RID_81557; FR900506; DSSTox_GSID_46354; BSPBio_001279; CHEMBL66247; L-679934; GTPL6784; DTXSID5046354; CHEBI:93221; HMS503O21; QJJXYPPXXYFBGM-LFZNUXCKSA-N; C44H69NO12; Prograf; HMS1792O21; HMS1990O21; HMS2093M19; HMS3403O21; Pharmakon1600-01503968; 15,19-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone, 5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-(2-(4-hydroxy-3-methoxycyclohexyl)-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-, (3S-(3R*(E(1S*,3S*,4S*)),4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*))-; EX-A1677; Tox21_112056; ABP000474; BDBM50030448; Prograft; BDBM50079777; LMPK04000003; NSC758659; s5003; AKOS005145901; ZINC169289411; AC-1182; AM81227; AT-2441; CS-1507;